Company

ResApp Health Ltd

ASX:RAP

ResApp Health Ltd (ASX:RAP) is listed on the Australian Securities Exchange.

31 stories · page 2 of 2

ResApp Health Ltd app to diagnose respiratory diseases from cough sounds

ResApp Health Ltd (ASX:RAP) has received institutional review board approval at the Massachusetts General Hospital in Boston, U.S. for the SMARTCOUGH-C study.

By Proactive 11/11/2016

Pharma & Biotech

ResApp Health Ltd awarded best venture capital raising of 2016

By Proactive 19/08/2016

Pharma & Biotech

ResApp Health Ltd to reveal clinical results

By Proactive 20/06/2016

Pharma & Biotech

ResApp Health Ltd app detects respiratory disease through a smart phone

By Proactive 16/06/2016

Pharma & Biotech

ResApp Health Ltd in ASX trading halt

By Proactive 18/04/2016

Pharma & Biotech

ResApp Health to reveal clinical study results

By Proactive 06/11/2015

Pharma & Biotech

ResApp Health in halt pending clinical study results

By Proactive 28/09/2015

Pharma & Biotech

ResApp Health expands clinical study for respiratory diagnostic technology

By Proactive 12/08/2015

Pharma & Biotech

Resapp Health, Galicia Energy among Thursday’s most traded

By Proactive 17/07/2015

Pharma & Biotech

ResApp Health re-lists on the ASX, to commercialise respiratory products

By Proactive 14/07/2015

Pharma & Biotech

Narhex Life Sciences completes acquisition of ResApp Diagnostics

By Proactive 03/07/2015